Literature DB >> 34363424

On-Demand Therapy for OFF Episodes in Parkinson's Disease.

C Warren Olanow1,2, Werner Poewe3, Olivier Rascol4, Fabrizio Stocchi5.   

Abstract

Levodopa is the most effective therapy for Parkinson's disease; however, chronic treatment is associated with the development of OFF episodes, in which there is a return of parkinsonian features following a dose of levodopa and prior to the onset of benefit from the subsequent dose. OFF episodes can be a major source of disability for PD patients and frequently result in depression, apathy and an unwillingness to participate in social activities. Most currently available medical and surgical therapies are designed to reduce total daily OFF time but do not provide a rapid and reliable "on-demand" therapy for individual OFF episodes. Indeed, responses to individual doses of levodopa during an acute OFF episode are unreliable, frequently leading to partial-ON, delayed-ON, or no-ON responses even at different times in the same patient. There are now 3 therapies that are available for the on-demand treatment of OFF episodes; subcutaneous injection of apomorphine, sublingual apomorphine film, and inhaled levodopa. The first has not enjoyed widespread use in the PD community, whereas the latter 2 therapies have only recently been approved. This review will consider the currently available on-demand therapies and their potential advantages and disadvantages.
© 2021 International Parkinson and Movement Disorder Society. © 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; inhaled levodopa; motor fluctuations; on-demand therapy; subcutaneous apomorphine; sublingual apomorphine film

Year:  2021        PMID: 34363424     DOI: 10.1002/mds.28726

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials.

Authors:  Zeya Yan; Wei Wang; Xinyu Tao; Wei Cheng; Gang Zuo; Zhouqing Chen; Zhong Wang; Gang Chen
Journal:  Neurol Sci       Date:  2022-07-30       Impact factor: 3.830

Review 2.  Closing the loop for patients with Parkinson disease: where are we?

Authors:  Hazhir Teymourian; Farshad Tehrani; Katherine Longardner; Kuldeep Mahato; Tatiana Podhajny; Jong-Min Moon; Yugender Goud Kotagiri; Juliane R Sempionatto; Irene Litvan; Joseph Wang
Journal:  Nat Rev Neurol       Date:  2022-06-09       Impact factor: 44.711

3.  Functional Covariance Connectivity of Gray and White Matter in Olfactory-Related Brain Regions in Parkinson's Disease.

Authors:  Yiqing Wang; Hongyu Wei; Shouyun Du; Hongjie Yan; Xiaojing Li; Yijie Wu; Jianbing Zhu; Yi Wang; Zenglin Cai; Nizhuan Wang
Journal:  Front Neurosci       Date:  2022-03-04       Impact factor: 4.677

Review 4.  Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?

Authors:  Stuart H Isaacson; Fernando L Pagan; Mark F Lew; Rajesh Pahwa
Journal:  Clin Park Relat Disord       Date:  2022-08-12

Review 5.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.